243 related articles for article (PubMed ID: 33380865)
1. The abscopal effect in head-and-neck squamous cell carcinoma treated with radiotherapy and nivolumab: a case report and literature review.
Forner D; Horwich P; Trites JR; Hollenhorst H; Bullock M; Lamond NWD
Curr Oncol; 2020 Dec; 27(6):330-335. PubMed ID: 33380865
[TBL] [Abstract][Full Text] [Related]
2. Abscopal Effect Following Immunotherapy and Combined Stereotactic Body Radiation Therapy in Recurrent Metastatic Head and Neck Squamous Cell Carcinoma: A Report of Two Cases and Literature Review.
Choi JS; Sansoni ER; Lovin BD; Lindquist NR; Phan J; Mayo LL; Ferrarotto R; Su SY
Ann Otol Rhinol Laryngol; 2020 May; 129(5):517-522. PubMed ID: 31875405
[TBL] [Abstract][Full Text] [Related]
3. Outcome of chemotherapy following nivolumab treatment for recurrent and/or metastatic head and neck squamous cell carcinoma.
Wakasaki T; Yasumatsu R; Uchi R; Taura M; Matsuo M; Komune N; Nakagawa T
Auris Nasus Larynx; 2020 Feb; 47(1):116-122. PubMed ID: 31128940
[TBL] [Abstract][Full Text] [Related]
4. Immunotherapy in Patients with Recurrent and Metastatic Squamous Cell Carcinoma of the Head and Neck.
Łasińska I; Kolenda T; Teresiak A; Lamperska KM; Galus Ł; Mackiewicz J
Anticancer Agents Med Chem; 2019; 19(3):290-303. PubMed ID: 30198439
[TBL] [Abstract][Full Text] [Related]
5. Randomized Phase II Trial of Nivolumab With Stereotactic Body Radiotherapy Versus Nivolumab Alone in Metastatic Head and Neck Squamous Cell Carcinoma.
McBride S; Sherman E; Tsai CJ; Baxi S; Aghalar J; Eng J; Zhi WI; McFarland D; Michel LS; Young R; Lefkowitz R; Spielsinger D; Zhang Z; Flynn J; Dunn L; Ho A; Riaz N; Pfister D; Lee N
J Clin Oncol; 2021 Jan; 39(1):30-37. PubMed ID: 32822275
[TBL] [Abstract][Full Text] [Related]
6. Immunotherapy orchestrates radiotherapy in composing abscopal effects: A strategic review in metastatic head and neck cancer.
Akbor M; Hung KF; Yang YP; Chou SJ; Tsai PH; Chien CS; Lin LT
J Chin Med Assoc; 2020 Feb; 83(2):113-116. PubMed ID: 31834023
[TBL] [Abstract][Full Text] [Related]
7. Abscopal Effect after Stereotactic Body Radiotherapy with Nivolumab for Lung Metastasis of Head and Neck Cancer: A Case Report.
Endo M; Fukuda Y; Okada K; Ogawa K; Nakamura M; Takahashi S; Kawahara M; Akahane K; Nagai Y; Yamaguchi H; Nishino H; Mori H; Shirai K
Case Rep Oncol; 2023; 16(1):1345-1352. PubMed ID: 37946746
[TBL] [Abstract][Full Text] [Related]
8. Anti-PD-1 monoclonal antibody-resistant esophageal squamous cell carcinoma showing the abscopal effect: A case report with T-cell receptor/B-cell receptor repertoire analysis.
Takehara Y; Mimura K; Suzuki Y; Watanabe Y; Yoshimoto Y; Saze Z; Sato H; Tamaki T; Kono K
Cancer Rep (Hoboken); 2023 Jul; 6(7):e1832. PubMed ID: 37165926
[TBL] [Abstract][Full Text] [Related]
9. Neoadjuvant immunoradiotherapy results in high rate of complete pathological response and clinical to pathological downstaging in locally advanced head and neck squamous cell carcinoma.
Leidner R; Crittenden M; Young K; Xiao H; Wu Y; Couey MA; Patel AA; Cheng AC; Watters AL; Bifulco C; Morris G; Rushforth L; Nemeth S; Urba WJ; Gough M; Bell RB
J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 33963014
[TBL] [Abstract][Full Text] [Related]
10. [Immunotherapy in head and neck squamous cell carcinoma : Abscopal effects in combination with radiotherapy, extraordinary responses in combination with chemotherapy, and pseudoprogression].
Brix N; Dunn L; Seiwert T; Belka C; Lauber K
Internist (Berl); 2020 Jul; 61(7):682-689. PubMed ID: 32462252
[TBL] [Abstract][Full Text] [Related]
11. Overcoming immune-resistance in laryngeal cancer: a case report of the abscopal effect and nivolumab beyond progression.
Marco F; Gianluca A; Mariagrazia T; Luca EP
Immunotherapy; 2022 Oct; 14(14):1089-1095. PubMed ID: 36040238
[TBL] [Abstract][Full Text] [Related]
12. Induction of the Abscopal Effect with Immunotherapy and Palliative Radiation in Metastatic Head and Neck Squamous Cell Carcinoma: A Case Report and Review of the Literature.
Shinde A; Novak J; Freeman ML; Glaser S; Amini A
Cureus; 2019 Mar; 11(3):e4201. PubMed ID: 31114720
[TBL] [Abstract][Full Text] [Related]
13. Fostering efficacy of anti-PD-1-treatment: Nivolumab plus radiotherapy in advanced non-small cell lung cancer - study protocol of the FORCE trial.
Bozorgmehr F; Hommertgen A; Krisam J; Lasitschka F; Kuon J; Maenz M; Huber PE; König L; Kieser M; Debus J; Thomas M; Rieken S
BMC Cancer; 2019 Nov; 19(1):1074. PubMed ID: 31703637
[TBL] [Abstract][Full Text] [Related]
14. Phase II Trial of Adjuvant Nivolumab Following Salvage Resection in Patients with Recurrent Squamous Cell Carcinoma of the Head and Neck.
Leddon JL; Gulati S; Haque S; Allen C; Palackdharry S; Mathews M; Kurtzweil N; Riaz MK; Takiar V; Nagasaka M; Patil Y; Zender C; Tang A; Cervenka B; McGrath J; Korn WM; Hinrichs BH; Jandarov R; Harun N; Sukari A; Wise-Draper TM
Clin Cancer Res; 2022 Aug; 28(16):3464-3472. PubMed ID: 35653116
[TBL] [Abstract][Full Text] [Related]
15. Abscopal effect and resistance reversion in nivolumab-treated non-small-cell lung cancer undergoing palliative radiotherapy: a case report.
Fiorica F; Belluomini L; Giuliani J; Urbini B; Milella M; Frassoldati A; Pilotto S; Giorgi C
Immunotherapy; 2021 Aug; 13(12):971-976. PubMed ID: 34180714
[TBL] [Abstract][Full Text] [Related]
16. Immunotherapy of head and neck squamous cell carcinoma (HNSCC). Immune checkpoint blockade.
Przybylski K; Majchrzak E; Weselik L; Golusiński W
Otolaryngol Pol; 2018 Sep; 72(6):10-16. PubMed ID: 30647199
[TBL] [Abstract][Full Text] [Related]
17. Effect of tumor burden and growth rate on treatment outcomes of nivolumab in head and neck cancer.
Suzuki C; Kiyota N; Imamura Y; Rikitake J; Sai S; Koyama T; Hyogo Y; Nagatani Y; Funakoshi Y; Toyoda M; Otsuki N; Nibu KI; Minami H
Int J Clin Oncol; 2020 Jul; 25(7):1270-1277. PubMed ID: 32277393
[TBL] [Abstract][Full Text] [Related]
18. ["Immunotherapy in head and neck squamous cell carcinoma"].
Marret G; Borcoman É; Le Tourneau C
Rev Prat; 2021 Apr; 71(4):396-399. PubMed ID: 34161005
[TBL] [Abstract][Full Text] [Related]
19. Initial analysis of the synergy of programmed cell death-1 (PD-1) inhibitor and concurrent chemoradiotherapy treatment for recurrent/metastatic head and neck squamous cell carcinoma patients.
Li L; Chen L; Yan L; Guo Y; Li F; Fan M; Lan M; Lai X; Zhou J; Huang Y; Xu P; Lang J; Feng M
Radiat Oncol; 2023 Jul; 18(1):109. PubMed ID: 37403098
[TBL] [Abstract][Full Text] [Related]
20. Durable complete remission with local therapies after neoadjuvant and adjuvant nivolumab in recurrent/metastatic head and neck cancer.
Cabezas-Camarero S; Iglesias-Moreno MC; Cerezo Druet E; Sotelo MJ; Merino-Menéndez S; Cabrera-Martín MN; Plaza-Hernández JC; Pérez-Segura P
Anticancer Drugs; 2023 Jun; 34(5):695-698. PubMed ID: 36730545
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
